Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairment and Insulin Resistance
NCT07220694
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This randomized, double-blind, placebo-controlled, 8-week clinical trial is designed to evaluate the effects of Sabroxy®, a standardized extract of Oroxylum indicum bark, on insulin resistance and cognitive function in adults with mild cognitive impairment and insulin resistance. A total of 120 participants (men and women, aged 40-80 years) who are non-smokers, with fasting glucose levels between 100-135 mg/dL, HOMA-IR value ≥ 2.0 to < 4.0, and a Montreal Cognitive Assessment (MoCA) score below 26, will be enrolled.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Insulin Resistance
- Mild Cognitive Impairment
- Cognitive Decline
- Neurodegenerative Disorders
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 40 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- SF Research Institute, Inc.
- Last updated on ClinicalTrials.gov
- January 28, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- San Francisco Research Institute · San Francisco, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.